- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment
- Join Join
Americans for Safe Access (ASA) estimates that 1,150 Californians on organ transplant lists use medical marijuana. That was hazardous to their health until a few days ago.
The danger was being kicked off the list for smoking marijuana. It happened to Norman B. Smith in 2011, two weeks away from a liver transplant, and it killed him the next year. But it shouldn’t happen to anyone else.
Assembly Bill 258—co-sponsored by the ASA, passed overwhelmingly in the Legislature and signed recently by Governor Brown—prevents hospitals from denying transplants to candidates based on their use of medical marijuana. In Smith’s case, his oncologist had prescribed the drug for his liver cancer.
When he introduced the bill, California State Assemblyman Marc Levine (D-San Rafael), said, “Arcane public health policies view medical cannabis patients as drug abusers.” Now they don’t, joining Arizona, Delaware, Illinois, Minnesota, New Hampshire, and Washington, which have similar laws.
Smith’s experience at Cedars-Sinai Medical Center in Los Angeles was the first to generate media exposure but he was quickly joined by another Cedars reject. Toni Trujillo was on the list for six years and moved from Pennsylvania for the last two years of treatment before being delisted in 2012.
Yami Bolanos, 58, was reportedly told she would be ineligible for a re-transplant of her 18-year-old kidney by the same doctor at theUniversity of California, San Francisco that recommended she use medical marijuana. The Santa Monica resident is also president of the Greater Los Angeles Collective Association (GLACA), a group of medical cannabis cooperatives.
Richard Hawthorne, who has hepatitis-C and cirrhosis of the liver, was denied a transplant by Stanford Medical Center last year, although a friend volunteered to be a donor.
Both Smith and Trujillo say they were told by the hospital that a primary reason for denial was the risk of infection caused by aspergillosis, a genus of common molds frequently seen growing on plants, trees and food. Marijuana dispensaries regularly test for the mold.
The fungus is considered a threat to people with suppressed immune function and a serious problem for people following transplants. But the legislative analysis written for the Senate noted that the Centers for Disease Control and Prevention (CDC) downplayed the threat and pointed out that people are exposed to it every day in the air they breathe.
The analysis also cited a study published in the American Journal of Transplantation, that cannabis use by patients undergoing transplants does not adversely impact survival rates.